Back to Search
Start Over
Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target?
- Source :
-
Stroke [Stroke] 2021 Aug; Vol. 52 (8), pp. 2707-2714. Date of Electronic Publication: 2021 Jun 15. - Publication Year :
- 2021
-
Abstract
- Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment. Here we review the current literature regarding cerebral amyloid angiopathy pathophysiology and treatment, as well as what is known of the fibrinolytic pathway and its interaction with amyloid. We postulate that tranexamic acid is a potential secondary stroke prevention treatment agent in sporadic cerebral amyloid angiopathy, although further research is required.
- Subjects :
- Amyloid beta-Peptides antagonists & inhibitors
Amyloid beta-Peptides blood
Antibodies, Monoclonal administration & dosage
Cerebral Amyloid Angiopathy blood
Cerebral Amyloid Angiopathy diagnosis
Cerebral Hemorrhage blood
Cerebral Hemorrhage diagnosis
Cerebral Hemorrhage drug therapy
Fibrinolysin metabolism
Humans
Tranexamic Acid administration & dosage
Antifibrinolytic Agents administration & dosage
Cerebral Amyloid Angiopathy drug therapy
Drug Delivery Systems methods
Fibrinolysin antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4628
- Volume :
- 52
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Stroke
- Publication Type :
- Academic Journal
- Accession number :
- 34126761
- Full Text :
- https://doi.org/10.1161/STROKEAHA.120.033107